Somatic mutations in LKB1, encoded by serine/threonine kinase 11 (STK11), occur in approximately 20-25% of lung adenocarcinoma (LUAD), while inactivating mutations in KEAP1 are observed in approximately 10-15% of LUAD (19–21). This evidence concerns the gene STK11 and lung adenocarcinoma.